Enzon Pharmaceuticals Stock Forecast, Price & News

Enzon Pharmaceuticals' stock was trading at $0.1693 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ENZN stock has increased by 84.0% and is now trading at $0.3115.
View which stocks have been most impacted by COVID-19.

Wall Street analysts have given Enzon Pharmaceuticals a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Enzon Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Enzon Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, February 17th 2021.
View our earnings forecast for Enzon Pharmaceuticals.

Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZN) posted its earnings results on Thursday, April, 30th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter. Enzon Pharmaceuticals had a negative return on equity of 20.29% and a negative net margin of 1,711.94%.
View Enzon Pharmaceuticals' earnings history.

Enzon Pharmaceuticals saw a increase in short interest in the month of December. As of December 31st, there was short interest totaling 43,700 shares, an increase of 241.4% from the December 15th total of 12,800 shares. Based on an average daily volume of 574,200 shares, the days-to-cover ratio is presently 0.1 days.
View Enzon Pharmaceuticals' Short Interest.

Some companies that are related to Enzon Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Exact Sciences (EXAS), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Novavax (NVAX).
View all of ENZN's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Enzon Pharmaceuticals investors own include Aeterna Zentaris (AEZS), CBL & Associates Properties (CBL), Pennsylvania Real Estate Investment Trust (PEI), Cannabics Pharmaceuticals (CNBX), Gran Tierra Energy (GTE), Golar LNG Partners (GMLP), Washington Prime Group (WPG), DHT (DHT), Hallador Energy (HNRG) and Medical Marijuana (MJNA).

Enzon Pharmaceuticals trades on the OTCMKTS under the ticker symbol "ENZN."

Shares of ENZN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ENZN stock can currently be purchased for approximately $0.31.

Enzon Pharmaceuticals has a market capitalization of $23.12 million and generates $210,000.00 in revenue each year.

The official website for Enzon Pharmaceuticals is www.enzon.com.

Enzon Pharmaceuticals' mailing address is 20 Commerce Drive Suite 135, Cranford NJ, 07016. The biotechnology company can be reached via phone at 732-980-4500 or via email at [email protected]